Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals robust financial performance with record-high revenue, improved gross margins, and a strong balance sheet. The optimistic guidance for future growth, driven by global expansion and pipeline development, supports a positive outlook. The absence of full-year guidance is a minor concern, but overall, the strategic initiatives and financial health indicate a strong positive impact on the stock price.
Key Financial Performance
Net VYJUVEK revenue $97.8 million for Q3 2025, showing sustained growth compared to the prior quarter. The growth was driven by patient additions, early traction in Europe, and mitigation of patient pausing impacts due to summer holidays.
Total net VYJUVEK revenue since launch Over $623 million, reflecting the cumulative revenue generated since the product's launch.
Gross margins 96% for Q3 2025, an increase from 93% in the prior quarter. The improvement was due to U.S. product manufacturing process optimizations and lower-cost batches after FDA approval of the optimized process.
Reimbursement approvals in the U.S. Over 615 approvals, with more than 40 new approvals since the last earnings call. This marks the second sequential quarter of acceleration in reimbursement approvals, attributed to the field team's efforts and sales force expansion.
Number of prescribers in the U.S. Exceeding 450, reflecting increased penetration into the community setting.
Cost of goods sold $4.3 million for Q3 2025.
Research and development expenses $14.6 million for Q3 2025.
General and administrative expenses $37.6 million for Q3 2025.
Net income $79.4 million for Q3 2025, which included one-time noncash tax benefits and the reversal of the Section 174 R&D capitalization requirement.
Cash and investments Over $864 million as of the end of Q3 2025, highlighting a strong balance sheet.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYJUVEK launch: Continued momentum in the U.S. with updated label expanding eligible patient population to include DEB patients from birth. Launched in Germany, France, and Japan with successful pricing negotiations in Japan.
New clinical program: Initiating a program for Hailey-Hailey disease, a rare genetic skin disease, leveraging HSV-1 gene delivery platform.
European market expansion: Launched VYJUVEK in Germany and France. In France, VYJUVEK is the first gene therapy approved for dispensing outside hospital settings. Received ASMR III designation in France, aiding pricing and reimbursement discussions.
Japanese market entry: Launched VYJUVEK in Japan after successful pricing negotiations. Japanese team fully staffed to support launch.
Global distributor partnerships: Contracted with regional specialty distributors for Central and Eastern Europe, Turkey, and the Middle East to expand VYJUVEK access.
Revenue growth: Net VYJUVEK revenue for Q3 was $97.8 million, with total revenue since launch exceeding $623 million. Gross margins at 96%.
Reimbursement approvals: Over 40 new U.S. reimbursement approvals since last update, totaling over 615 approvals. Expanded field force fully hired and deployed.
Manufacturing efficiencies: Optimized U.S. manufacturing process approved, improving gross margins. Ex-U.S. approval pending.
Pipeline expansion: Expanded clinical programs in respiratory, oncology, ophthalmology, and dermatology. Received FDA platform therapy designation for HSV-1 gene delivery platform.
New product development: Developing KB111 for Hailey-Hailey disease, with clinical trials starting in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access and Pricing Challenges: The company faces challenges in pricing and reimbursement negotiations in Europe and Japan, which could impact revenue growth and market penetration.
Regulatory Hurdles: The need for FDA and other regulatory body approvals for optimized manufacturing processes and new clinical programs could delay product launches and increase costs.
Supply Chain and Manufacturing Risks: The optimized manufacturing process for the U.S. market has not yet been approved for ex-U.S. markets, potentially affecting gross margins and product availability.
Economic and Operational Uncertainties: Quarter-to-quarter revenue variability in the U.S. market and the potential for waviness in revenue growth could impact financial stability.
Competitive Pressures: The company operates in a highly competitive market, which could affect its ability to maintain market share and achieve long-term growth.
Strategic Execution Risks: The global launch of VYJUVEK and the expansion of the clinical pipeline require significant operational discipline and resources, posing risks to execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
VYJUVEK Label Update: The updated U.S. label for VYJUVEK expands the eligible patient population to include DEB patients from birth and provides full flexibility in dosing. This change is expected to positively impact compliance and adoption in the future.
European Market Expansion: VYJUVEK has launched in Germany and France, with early access and pricing discussions progressing. The company expects steady growth in patient inclusion and broader prescribing patterns in Europe.
Japanese Market Launch: VYJUVEK has been launched in Japan following successful pricing negotiations. Modest revenue contribution is expected in 2025, with significant growth anticipated in 2026.
Global Distributor Network: Krystal is contracting with regional specialty distributors to commercialize VYJUVEK in Central and Eastern Europe, Turkey, and the Middle East, aiming to expand access to thousands more DEB patients globally.
Pipeline Progress: Multiple readouts are expected in the coming months, including interim data for KB407 (cystic fibrosis) by year-end, and updates on KB408 (AATD lung disease) and KB803 (corneal abrasions in DEB patients) in 2026.
New Clinical Program for Hailey-Hailey Disease: Krystal is initiating a study for KB111 to treat Hailey-Hailey Disease, with trials expected to start in the first half of next year.
Financial Guidance: The company has revised its full-year non-GAAP R&D and SG&A guidance to $145 million to $155 million, reflecting disciplined execution and confidence in future profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the focus for the ex-U.S. launch, breadth or depth of prescribers?
A:The focus is on accelerating patient access to physicians, starting with centers of excellence and gradually expanding into the community.
Q:What was optimized in the process leading to better gross margins, and when will it be expanded to ex-U.S. markets?
A:The optimization involved moving to a larger bioreactor, which is approved in the U.S. The scale-up process has been filed in Europe, and approval is expected next year.
Q:What are the expectations for ex-U.S. revenue contribution and pricing for the next year?
A:Germany is off to a good start with 10+ centers prescribing. The launch is expected to be steady without early bolus. Pricing varies by country, with Germany allowing free pricing for the first 6 months. Negotiations are ongoing in France, and pricing is influenced by efficacy and disease severity.
Q:What are the gating aspects of the NK trial, and has enrollment started?
A:Enrollment has started with several sites up and running globally. Most sites are expected to be operational by year-end, and interim data is targeted for mid-next year.
Q:How many null patients will be included in the CF study, and what constitutes success?
A:The study will include a minimum of 3 null patients, focusing on molecular correction. Success is defined as robust CFTR expression across lung biopsies, with 5-10% expression considered significant.
Q:Why is the selected dose for the NK trial considered appropriate, and will one efficacy study suffice for approval?
A:The dose is based on animal studies showing clear pharmacokinetics and expression. One efficacy trial is expected to suffice due to the rare disease status and regulatory guidance.
Q:Will prior ocular HSV infection impact the NK trial, and what will the initial data set include?
A:Patients with prior HSV infection are not excluded unless they have an active infection. The initial data set will include complete healing at 8 weeks compared to placebo.
Q:Will there be full-year revenue guidance for VYJUVEK next year?
A:No, due to multiple ongoing launches and varying distribution, revenue guidance will not be provided for 2026.
Q:What was the U.S. vs. ex-U.S. sales contribution for VYJUVEK in Q3?
A:The company did not break down sales by geography this quarter but plans to start segment reporting in 2026.
Q:What contributed to the growth in reimbursement approvals for VYJUVEK, and what is the path to 60% penetration?
A:Growth was driven by an increased sales force addressing community settings. The path to 60% penetration (720 approvals) is expected within 1-2 quarters.
Q:What are the expectations for KB408 with repeat dosing, and is site expansion a priority?
A:An uptick in AAT levels is expected with repeat dosing, but specifics are not disclosed. Site expansion is limited due to the complexity of procedures like bronchoscopy and lung lavage.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the percentage breakdown of U.S. vs. ex-U.S. sales for VYJUVEK in Q3, citing accounting and auditor-driven reasons. They also did not disclose specific expectations for the uptick in AAT levels with repeat dosing for KB408.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASMR
ATPC
Enrollment
Europe VYJUVEK
FDA approval
FEV
France VYJUVEK
HHD patient
Hailey Disease
Italy
KB combination
KYANITE
Krish Founder
Krystal
NSCLC
Phase III
RD
VYJUVEK access
acceleration
achievement
award
cell ATPase
combination chemotherapy
compliance future
contribution
delivery platform
designation program
disease skin
distributor
efficiency
enrollment
gene
milestone
network
process
revenue
study KB
trial
KRYS Transcript
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Positive5-4
The earnings call highlights strong financial performance, with significant net income and EPS growth, and a robust cash position. The Q&A session indicates positive global market trends and strategic pipeline developments. Despite some management ambiguity, the overall sentiment is optimistic, supported by strong ex-U.S. growth, positive KB803 launch expectations, and successful at-home administration of VYJUVEK. These factors suggest a positive stock price movement over the next two weeks.
Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call Transcript
Positive2-17
The earnings call highlights strong financial performance, global market expansion, and strategic pipeline developments. Despite some uncertainties in pricing and compliance, the overall sentiment is positive due to strong revenue growth, operational efficiency, and a well-positioned cash reserve. The Q&A section reinforces this with management's confidence in global demand and strategic focus on pipeline investment. The absence of immediate stock buybacks is offset by the promising outlook on market expansion and product adoption, suggesting a positive stock price movement.
Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
KRYS Slides
KRYS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
